DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
December 2024: Zepbound became the first FDA-approved medication for obstructive sleep apnea + obesity. SURMOUNT-OSA showed 25 events/hour AHI reduction, 50% remission. Medicare covers under dual indication.
December 2024 FDA approval — game-changer for OSA patients
Zepbound (tirzepatide) became the first medication FDA-approved for obstructive sleep apnea + obesity. SURMOUNT-OSA trial: 25 events/hour AHI reduction at 52 weeks. 50% of patients achieved remission (AHI <5). This unlocks Medicare coverage despite Part D weight-loss exclusion — massive change for senior + Medicare populations.
~40% of obese adults have undiagnosed OSA. Home sleep test reveals it quickly. Diagnosis unlocks Zepbound\'s dual indication AND improves cardiovascular outcomes regardless of GLP-1 choice.
$249 · FDA-cleared · Mail-in results
Wesper sends a patch you wear for 2-3 nights at home. AI analysis + board-certified sleep specialist read. Results in 5-7 days. Often cheaper than in-clinic polysomnography ($800-2000) with similar accuracy for OSA diagnosis.
For ~50% of patients with OSA + obesity, yes — SURMOUNT-OSA showed 50% achieved remission (AHI <5/hour) at 52 weeks. Mean reduction was 25 events/hour. Remaining 50% still saw significant improvement but didn't reach remission threshold. Even non-remission patients often reduce CPAP pressure requirements.
Only with sleep specialist re-evaluation. Don't self-discontinue CPAP. Need: repeat sleep study at 6 months on Zepbound showing AHI <5 with confirmed weight loss. ~30% of remitters can fully discontinue; others step down to dental device or positional therapy.
Yes — this is the first FDA-approved GLP-1 indication that Medicare DOES cover (vs Medicare's statutory weight-loss exclusion). Medicare Part D covers Zepbound for OSA + obesity. Documentation required: sleep study showing OSA + BMI ≥30 + AHI ≥5/hour.
Need: (1) Sleep study showing OSA (AHI ≥5/hour), (2) BMI ≥30, (3) ICD-10 codes G47.33 (OSA) + E66.9 (obesity). If you suspect undiagnosed OSA — common in obesity patients — get a sleep study. Home sleep test ~$300-500 self-pay; Wesper at-home patch ~$249.
If you snore, have witnessed apneas, daytime sleepiness, or BMI ≥35 — yes. Sleep apnea is dramatically underdiagnosed in obesity patients. Diagnosis opens dual-indication pathway for Zepbound (insurance pathway better than weight-loss-only) and improves long-term cardiovascular outcomes.
Wegovy + Ozempic also reduce OSA severity via weight loss but aren't FDA-indicated for OSA. Only Zepbound has the formal OSA + obesity indication. For insurance purposes, Zepbound is the clear choice if OSA is present.
Don\'t self-discontinue CPAP. Stopping CPAP without confirmed OSA remission via repeat sleep study carries cardiovascular risk. Work with sleep specialist for stepwise reduction as weight loss progresses.